cagrilintide glp 1 (2.5mg) / GLP-1 S (2.5mg) – Performance Peptides Cagrilintide (2.5mg) / GLP-1 S
Description
In two analyses of spontaneous reports from the US Food and Drug Administrations adverse event reporting system database, the reporting rates of thyroid cancer were 4.7 and 8 times higher, respectively, for GLP1 receptor agonists compared with other diabetes drugs.23 In a meta-analysis based on 15 clinical trials that included at least one thyroid cancer outcome event, the odds ratio for thyroid cancer associated with GLP1 receptor agonists was 1.49 (95% confidence interval 0.83 to 2.66)
Yun SP, Kam TI, Panicker N, Kim S, Oh Y, Park JS, et al
The HPA dataset includes three normal salivary-gland tissue samples (ages 2168
Obesity poses a huge burden to the healthcare system and society
No prior appointment is required
The GLP-1 honeymoon period is a window of opportunity, not the final solution
